CAS No 1256963-02-6 LEE011；RIBOCICLIB Pharmaceutical Intermediates
Overview
LEE011, commonly known as RIBOCICLIB, is a potent and selective inhibitor of cell cycle-dependent kinases 4 and 6 (CDK4/6).
It is mainly used to treat hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer. By inhibiting CDK4/6, RIBOCICLIB can effectively disrupt the cell cycle and thus inhibit tumor cell proliferation.
This makes it an important component of combination therapy for advanced breast cancer, providing patients with a valuable treatment option that can improve efficacy and prolong survival.
Physical and chemical properties
- Solubility: Soluble in dimethyl sulfoxide (DMSO) and methanol, slightly soluble in water, easy to prepare into various dosage forms.
- Melting point: approx. 150-155 °C
- Stability: RIBOCICLIB exhibits good stability under recommended storage conditions, ensuring longer shelf life and reliability in therapeutic applications.
These properties make LEE011 suitable for formulating a variety of drug products, including tablets and oral solutions.
1. Targeted Therapy: RIBOCICLIB provides a targeted approach to cancer treatment by specifically inhibiting CDK4/6, which plays a key role in cell cycle regulation. This targeted action minimizes damage to normal cells and thus reduces side effects compared to traditional chemotherapy.
2. Efficacy of Combination Therapy: Clinical studies have shown that RIBOCICLIB, when used in combination with aromatase inhibitors or other hormonal therapies, can significantly improve progression-free survival in patients with HR+/HER2- breast cancer.
3. Regulatory Compliance: Our LEE011 is manufactured in accordance with international pharmaceutical standards, ensuring that it meets the strict requirements set by health authorities.
4. Research and Development Support: We provide comprehensive technical support and documentation to assist researchers and pharmaceutical companies in the development process.
As a factory integrating production and trading, we are committed to providing customers with high-quality LEE011 (RIBOCICLIB). Our obsession with quality is reflected in our advanced manufacturing process and strict quality control measures.
- Expertise: Our dedicated team of professionals is dedicated to research and development, ensuring we are always at the forefront of pharmaceutical innovation.
- Customer-centric approach: We prioritize our customers' needs, providing customized solutions and responsive customer service to support their specific requirements.
- Sustainability: We are committed to using sustainable practices in our manufacturing process, ensuring minimal impact on the environment while maintaining product quality.
In conclusion, LEE011 (RIBOCICLIB) is an important pharmaceutical ingredient that provides numerous benefits for the treatment of hormone receptor-positive breast cancer. With our comprehensive production capabilities, high quality standards, and commitment to customer satisfaction, we are your ideal partner in the pharmaceutical industry.
Choose our LEE011 (RIBOCICLIB) for your formulation and experience the difference in quality and efficacy. For inquiries or to place an order, please contact us today!